Cyclosporine and Vitiligo - a phase IV clinical study of FDA data

Summary:

Vitiligo is reported as a side effect among people who take Cyclosporine (cyclosporine), especially for people who are male, 50-59 old, also take Mycophenolate Mofetil, and have Bone marrow conditioning regimen.

The phase IV clinical study analyzes which people have Vitiligo when taking Cyclosporine. It is created by eHealthMe based on reports of 58,335 people who have side effects when taking Cyclosporine from the FDA, and is updated regularly.

What is Cyclosporine?

Cyclosporine has active ingredients of cyclosporine. It is often used in psoriasis. eHealthMe is studying from 58,714 Cyclosporine users. Check the latest studies of Cyclosporine.

What is Vitiligo?

Vitiligo (pigment is lost from areas of the skin) is found to be associated with 167 drugs and 307 conditions by eHealthMe. Check the latest studies of Vitiligo.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 25, 2026

58,335 people reported to have side effects when taking Cyclosporine.
Among them, 14 people (0.02%) have Vitiligo.

Among these 14 people:

What is the gender of people who have Vitiligo when taking Cyclosporine? *

female: 50 %
male: 50 %

What is the age of people who have Vitiligo when taking Cyclosporine? *

What are other drugs people take besides Cyclosporine? *

What are other side effects people have besides Vitiligo? *

Joint Pain: 6 people, 42.86%
Herpes Zoster: 6 people, 42.86%
Cushingoid (obesity and weakening of the muscles): 5 people, 35.71%
High Blood Pressure: 4 people, 28.57%
Red Blood Cell Sedimentation Rate Increased: 4 people, 28.57%
Drug Resistance (reduction in effectiveness of a drug): 4 people, 28.57%
Juvenile Rheumatoid Arthritis (joint inflammation in children due to systemic disease): 4 people, 28.57%
Joint Effusion (presence of extra fluid in joint covering): 4 people, 28.57%
Obliterative Bronchiolitis (bronchiolar inflammation): 4 people, 28.57%
Osteopenia (a condition where bone mineral density is lower than normal): 4 people, 28.57%

What are the existing conditions these people have? *

Bone Marrow Conditioning Regimen: 5 people, 35.71%
Juvenile Rheumatoid Arthritis (joint inflammation in children due to systemic disease): 4 people, 28.57%
Uveitis (inflammation of the uvea): 1 person, 7.14%
Optic Atrophy (the loss of a proportion of optic disc nerve fibres): 1 person, 7.14%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 1 person, 7.14%
Herpes Ophthalmic (eye infection caused by herpes simplex virus (hsv)): 1 person, 7.14%
Detachment Of Retinal Pigment Epithelium: 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Cyclosporine and have Vitiligo?

- Check whether Vitiligo is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cyclosporine:

Cyclosporine (58,714 reports)

Vitiligo treatments and more:

Vitiligo (3,513 reports)

Browse all side effects of Cyclosporine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Vitiligo:

Vitiligo (167 drugs)

Browse all the conditions that are associated with Vitiligo:

Vitiligo (307 conditions)

Related publications that referenced our studies

O’Brien FE, O’Connor RM, Clarke G, Donovan MD, Dinan TG, Griffin BT, Cryan JF, "The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram", Behavioural brain research, 2014 Mar .
O’Brien FE, O’Connor RM, Clarke G, Donovan MD, Dinan TG, Griffin BT, Cryan JF, "The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram", Behavioural brain research, 2014 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on cyclosporine (the active ingredients of Cyclosporine) and Cyclosporine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.